Source: BioSpace

Calliditas Therapeutics: Exercise of Over-allotment Option and End of the Stabilization Period - July 02, 2020

Citigroup Global Markets Inc., in its capacity as Joint Global Coordinator, notifies that the stabilization period relating to Calliditas Therapeutics AB 's American Depositary Shares, traded on The Nasdaq Global Select Market has ended and no further stabilization transactions will be effected.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Renee Aguiar-Lucander's photo - CEO of Calliditas

CEO

Renee Aguiar-Lucander

CEO Approval Rating

90/100

Calliditas is a pharmaceutical company that develops and commercializes therapeutics for the treatment of inflammatory kidney diseases. Read more